Monetize SBIR Procurement Gaps via Specialized Vendor Directory
- Organization
- National Science Foundation (SBIR Program)
- Sector
- SBIR-funded biotechs needing specialized vendor procurement
- Location
- United States
Source reference
Executive summary
Current state
NSF awarded $305,000 SBIR Phase I funding to AICONIC BIOSCIENCES for developing gene therapy to overcome AAV cargo size limitations, creating a structural commercial gap where cash-rich but bandwidth-poor biotechs must spend non-dilutive capital quickly while navigating complex technical and regulatory challenges.
Market catalyst
SBIR-funded biotechs like AICONIC have $305k non-dilutive capital that must be spent within 18 months on specialized services (AAV manufacturing, animal models, regulatory consulting) but lack the procurement bandwidth and industry connections to efficiently identify and vet qualified vendors.
This report is synthesized intelligence, not verified instruction. Always confirm against the primary source before acting. Review the full legal disclaimer before proceeding.
Field notes
Intelligence ledger
Add new evidence, corrections, or practical context to this directive. Keep claims attributable to a source where possible.
Sign in to add intelligence or vote on a field note.
Field intel logs: [ 0 ] entries. No operative updates submitted for this directive. Submit intel to claim clearance.